Newly developed anti-angiogenic therapy in non-small cell lung cancer.

about

Newly developed anti-angiogenic therapy in non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q52668159

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Newly developed anti-angiogenic therapy in non-small cell lung cancer.

@en

Newly developed anti-angiogenic therapy in non-small cell lung cancer.

@nl

type

Item

label

Newly developed anti-angiogenic therapy in non-small cell lung cancer.

@en

Newly developed anti-angiogenic therapy in non-small cell lung cancer.

@nl

prefLabel

Newly developed anti-angiogenic therapy in non-small cell lung cancer.

@en

Newly developed anti-angiogenic therapy in non-small cell lung cancer.

@nl

P1476

Newly developed anti-angiogenic therapy in non-small cell lung cancer.

@en

P2093

Chunhua Zhou

http://www.w3.org/2001/XMLSchema#string

Haiyan Yang

http://www.w3.org/2001/XMLSchema#string

Jingjing Qu

http://www.w3.org/2001/XMLSchema#string

Nong Yang

http://www.w3.org/2001/XMLSchema#string

Xue Chen

http://www.w3.org/2001/XMLSchema#string

Yongchang Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Angiogenesis as a therapeutic target

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.

A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).

P304

10147-10163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23755

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29515799

http://www.w3.org/2001/XMLSchema#string

P932

5839380

http://www.w3.org/2001/XMLSchema#string